Marek Krogulec

1.7k citations

10 papers · 675 indexed · 1 hit paper · h-index 6

Impact in

Rheumatology top 2%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
Hematology top 5%
- Autoimmune and Inflammatory Disorders Research

Papers in ⓘ

Rheumatology 8
- Rheumatoid Arthritis Research and Therapies 8
- Systemic Lupus Erythematosus Research 1
Immunology 6
- Biosimilars and Bioanalytical Methods 5
- Psoriasis: Treatment and Pathogenesis 1

Co-authors: Charles Ludivico (2 shared papers)Terence Rooney (2 shared papers)Scott D. Beattie (2 shared papers)William L. Macias (2 shared papers)Omid Zamani (2 shared papers)Josef S Smolen (2 shared papers)Joel Kremer (1 shared paper)Tracy Cardillo (1 shared paper)
Journals: Annals of the Rheumatic Diseases (3 papers)New England Journal of Medicine (2 papers)Lara D. Veeken (1 paper)Advances in Therapy (1 paper)Arthritis Research & Therapy (1 paper)
Partner nations: United States South Korea Poland

In The Last Decade

Marek Krogulec

9 papers receiving 654 citations

Hit Papers

align trajectories log scale

Baricitinib in Patients with Refractory Rheumatoid Arthritis 2016 · 458 citations

Peers

Countries citing papers authored by Marek Krogulec

Since Specialization

Citations

This map shows the geographic impact of Marek Krogulec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marek Krogulec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marek Krogulec more than expected).

Fields of papers citing papers by Marek Krogulec

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marek Krogulec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marek Krogulec. The network helps show where Marek Krogulec may publish in the future.

Co-authors

The 25 scholars most cited alongside Marek Krogulec, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Marek Krogulec Line = papers co-authored together Marek Krogulec links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work
1	Baricitinib in Patients with Refractory Rheumatoid Arthritis New England Journal of Medicine ·Mark C. Genovese, Joel Kremer, Omid Zamani, Charles Ludivico, Marek Krogulec, Li Xie, Scott D. Beattie, Alisa E. Koch, Tracy Cardillo, Terence Rooney, William L. Macias, Stephanie de Bono, Douglas Schlichting, Josef S Smolen Hit paper breakdown →	2016	458
2	Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis New England Journal of Medicine ·Paul Emery, Mohammed Hammoudeh, Oliver FitzGerald, Bernard Combe, E. Martín‐Mola, Maya H Buch, Marek Krogulec, Theresa M. Williams, Stefanie Gaylord, Ronald Pedersen, Jack F. Bukowski, Bonnie Vlahos	2014	134
3	Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study Annals of the Rheumatic Diseases ·C. Daïen, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure, Sophie Biguenet, Didier Scherrer, Julien Santo, Hartmut J. Ehrlich, Patrick Durez	2022	23
4	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study Arthritis Research & Therapy ·Jonathan Kay, Janusz Jaworski, Rafał Wojciechowski, Piotr Wiland, Anna Dudek, Marek Krogulec, Sławomir Jeka, Agnieszka Zielińska, Jakub Trefler, Katarzyna Bartnicka-Maslowska, Magdalena Krajewska–Włodarczyk, Piotr Adrian Klimiuk, Sang Joon Lee, Yun Ju Bae, Go Eun Yang, Jae Kyoung Yoo, Daniel E. Furst, Edward Keystone	2021	22
5	OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study Annals of the Rheumatic Diseases ·M. C. Genovese, Joel M. Kremer, Omid Zamani, Charles Ludivico, Marek Krogulec, Lechun Xie, Scott D. Beattie, A E Koch, T. Cardillo, Terence Rooney, William L. Macias, D. Schlichting, Josef S Smolen	2015	20
6	Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis Lara D. Veeken ·Daniel E. Furst, Janusz Jaworski, Rafał Wojciechowski, Piotr Wiland, Anna Dudek, Marek Krogulec, Sławomir Jeka, Agnieszka Zielińska, Jakub Trefler, Katarzyna Bartnicka-Maslowska, Magdalena Krajewska–Włodarczyk, Piotr Adrian Klimiuk, Sang Joon Lee, Sung Hyun Kim, Yun Ju Bae, Go Eun Yang, Jae Kyoung Yoo, Jonathan Kay, Edward Keystone	2021	12
7	Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47 RMD Open ·Josef S Smolen, Jakub Trefler, Artur Racewicz, Janusz Jaworski, Agnieszka Zielińska, Marek Krogulec, Sławomir Jeka, Rafał Wojciechowski, Katarzyna Kolossa, Anna Dudek, Magdalena Krajewska–Włodarczyk, Paweł Hrycaj, Piotr Adrian Klimiuk, Gerd R Burmester, Sung Hyun Kim, Yunju Bae, Go Eun Yang, Yeonsoon Jung, JiWoo Hong, Edward Keystone	2024	3
8	AB0198 EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB BIOSIMILAR: 100 MG/ML) IN COMPARISON WITH THE MAINTAINED TREATMENT (CT-P17 OR REFERENCE ADALIMUMAB) IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: 1-YEAR RESULT Annals of the Rheumatic Diseases ·Daniel E. Furst, Edward Keystone, Jonathan Kay, Janusz Jaworski, Rafał Wojciechowski, Piotr Wiland, Anna Dudek, Marek Krogulec, Sławomir Jeka, Agnieszka Zielińska, Jakub Trefler, Katarzyna Bartnicka-Maslowska, Magdalena Krajewska–Włodarczyk, Piotr Adrian Klimiuk, S. J. Lee, S. H. Kim, Yunju Bae, Go Eun Yang, Jae Kyoung Yoo, T. Kim	2021	2
9	Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study Advances in Therapy ·Mark Lebwohl, John Koo, Janusz Jaworski, Jakub Trefler, Stefan Daniluk, Anna Dudek, Wojciech Baran, Witold Owczarek, Joanna Kolinek, Paweł Brzewski, Mariusz Sikora, Marek Krogulec, SungHyun Kim, Yun Ju Bae, DaBee Jeon, Eunjin Choi, JungBin Cha, HyunJin Lee, Su‐Jin Choi, David M. Pariser	2025	1
10	Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis Clinical Drug Investigation ·Gerd R Burmester, Jakub Trefler, Artur Racewicz, Janusz Jaworski, Agnieszka Zielińska, Marek Krogulec, Sławomir Jeka, Rafał Wojciechowski, Katarzyna Kolossa, Anna Dudek, Magdalena Krajewska–Włodarczyk, Paweł Hrycaj, Piotr Adrian Klimiuk, Sung Hyun Kim, JeeHye Suh, Go Eun Yang, YunAh Kim, Yeonsoon Jung, G.S. Park, Josef S Smolen	2025	0

About Marek Krogulec

Marek Krogulec is a scholar working on Rheumatology, Immunology, Hematology, Economics and Econometrics and Pediatrics, Perinatology and Child Health, having authored 10 papers that have together received 675 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (8 papers), Biosimilars and Bioanalytical Methods (5 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers), Pharmaceutical studies and practices (2 papers), Autoimmune and Inflammatory Disorders Research (2 papers), Psoriasis: Treatment and Pathogenesis (1 paper), Lymphoma Diagnosis and Treatment (1 paper) and Systemic Lupus Erythematosus Research (1 paper). The work is most often cited by research in Rheumatology (493 citations), Hematology (244 citations), Genetics (160 citations), Immunology (194 citations) and Oncology (134 citations). Marek Krogulec has collaborated with scholars based in United States, South Korea and Poland. Frequent co-authors include Charles Ludivico, Terence Rooney, Scott D. Beattie, William L. Macias, Omid Zamani, Josef S Smolen, Joel Kremer, Tracy Cardillo, Alisa E. Koch and Mark C. Genovese. Their work appears in journals such as Annals of the Rheumatic Diseases, New England Journal of Medicine, Lara D. Veeken, Advances in Therapy and Arthritis Research & Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact